Efficiency of XELOX Neoadjuvant Chemotherapy in Gastric Cancer
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate that capecitabine/oxaliplatin as perioperative
chemotherapy is superior or not to operation directly for locally advanced gastric cancer in
terms of 3 year disease-free survival (DFS) rate.